On January 10, the reporter learned from Beida Pharmaceutical Co., Ltd. that beiantin, the company's first macromolecular biological product, issued the first batch of prescriptions in many places across the country, and officially began to benefit tumor patients. The incidence rate of lung cancer is the first malignant tumor in China, and the proportion of non-small cell lung cancer (NSCLC) is quite high. The incidence rate of colorectal cancer has also increased in recent years. In November 2021, beianting was approved for marketing. The approved indications are metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer. At present, the supplementary application for four new indications of betaine has been accepted by the State Drug Administration. Betaine is a biological analogue of bevacizumab. Bevacizumab is a recombinant humanized monoclonal antibody, which can selectively bind to human vascular endothelial growth factor (VEGF), block its biological activity, reduce tumor angiogenesis and inhibit tumor growth. It is understood that betaine has passed a comprehensive quality Similarity Study and non clinical similarity study, and its performance in clinical comparison test is highly similar to that of the original drug in PK characteristics, clinical effectiveness, safety and immunogenicity. (outlook new era)